{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:03:20Z","timestamp":1790665400870,"version":"4.1.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T00:00:00Z","timestamp":1683763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T00:00:00Z","timestamp":1683763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1007\/s40265-023-01877-6","type":"journal-article","created":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T16:57:48Z","timestamp":1683824268000},"page":"717-723","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Ravulizumab: A Review in Generalised Myasthenia Gravis"],"prefix":"10.1007","volume":"83","author":[{"given":"Connie","family":"Kang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,11]]},"reference":[{"issue":"5","key":"1877_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1056\/EVIDoa2100066","volume":"1","author":"T Vu","year":"2022","unstructured":"Vu T, Meisel A, Mantegazza R, et al. Terminal complement inhibitor ravulizumab in generalized myasthenia gravis. NEJM Evid. 2022;1(5):1\u201312.","journal-title":"NEJM Evid."},{"issue":"8","key":"1877_CR2","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s40265-022-01726-y","volume":"82","author":"D Menon","year":"2022","unstructured":"Menon D, Bril V. Pharmacotherapy of generalized myasthenia gravis with special emphasis on newer biologicals. Drugs. 2022;82(8):865\u201387.","journal-title":"Drugs"},{"key":"1877_CR3","doi-asserted-by":"publisher","first-page":"604","DOI":"10.3389\/fneur.2020.00604","volume":"11","author":"ME Farrugia","year":"2020","unstructured":"Farrugia ME, Goodfellow JA. A practical approach to managing patients with myasthenia gravis-opinions and a review of the literature. Front Neurol. 2020;11:604.","journal-title":"Front Neurol"},{"issue":"3","key":"1877_CR4","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1007\/s13311-022-01181-3","volume":"19","author":"F Vanoli","year":"2022","unstructured":"Vanoli F, Mantegazza R. Antibody therapies in autoimmune neuromuscular junction disorders: approach to myasthenic crisis and chronic management. Neurotherapeutics. 2022;19(3):897\u2013910.","journal-title":"Neurotherapeutics"},{"issue":"2","key":"1877_CR5","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/S1474-4422(21)00463-4","volume":"21","author":"JJGM Verschuuren","year":"2022","unstructured":"Verschuuren JJGM, Palace J, Murai H, et al. Advances and ongoing research in the treatment of autoimmune neuromuscular junction disorders. Lancet Neurol. 2022;21(2):189\u2013202.","journal-title":"Lancet Neurol"},{"issue":"3","key":"1877_CR6","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","volume":"96","author":"P Narayanaswami","year":"2021","unstructured":"Narayanaswami P, Sanders DB, Wolfe G, et al. International consensus guidance for management of myasthenia gravis. Neurology. 2021;96(3):114\u201322.","journal-title":"Neurology"},{"key":"1877_CR7","unstructured":"US Food & Drug Administration. SOLIRIS\u00ae (eculizumab) injection, for intravenous use: US prescribing information. 2020. https:\/\/www.accessdata.fda.gov. Accessed 3 Apr 2023."},{"key":"1877_CR8","unstructured":"European Medicines Agency. Soliris (eculizumab): EU summary of product characteristics. 2022. https:\/\/www.ema.europa.eu. Accessed 3 Apr 2023."},{"issue":"4","key":"1877_CR9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0195909","volume":"13","author":"D Sheridan","year":"2018","unstructured":"Sheridan D, Yu ZX, Zhang Y, et al. Design and preclinical characterization of ALXN1210: a novel anti-C5 antibody with extended duration of action. PLoS ONE. 2018;13(4): e0195909.","journal-title":"PLoS ONE"},{"key":"1877_CR10","unstructured":"Alexion Pharmaceuticals Inc. ULTOMIRIS (ravulizumab-cwvz) injection, for intravenous use: US prescribing information. 2022. https:\/\/www.accessdata.fda.gov. Accessed 3 Apr 2023."},{"key":"1877_CR11","unstructured":"European Medicines Agency. Ultomiris (ravulizumab): EU summary of product characteristics. 2022. https:\/\/www.ema.europa.eu. Accessed 3 Apr 2023."},{"key":"1877_CR12","unstructured":"Pharmaceuticals and Medical Devices Agency. ULTOMIRIS intravenous infusion 300mg \/ ULTOMIRIS HI intravenous infusion 300mg\/3mL\/ULTOMIRIS HI intravenous infusion 1100mg\/11mL: Japanese prescribing information. 2022. https:\/\/www.pmda.go.jp. Accessed 3 Apr 2023."},{"issue":"5","key":"1877_CR13","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1007\/s40265-021-01481-6","volume":"81","author":"YY Syed","year":"2021","unstructured":"Syed YY. Ravulizumab: a review in atypical haemolytic uraemic syndrome. Drugs. 2021;81(5):587\u201394.","journal-title":"Drugs"},{"issue":"9","key":"1877_CR14","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s40267-019-00663-3","volume":"35","author":"K McKeage","year":"2019","unstructured":"McKeage K, Lyseng-Williamson KA. Ravulizumab in paroxysmal nocturnal hemoglobinuria: a profile of its use. Drugs Ther Perspect. 2019;35(9):405\u201312.","journal-title":"Drugs Ther Perspect."},{"issue":"23","key":"1877_CR15","doi-asserted-by":"publisher","first-page":"4777","DOI":"10.1182\/blood.V126.23.4777.4777","volume":"126","author":"L Sahelijo","year":"2015","unstructured":"Sahelijo L, Mujeebuddin A, Mitchell D, et al. First in human single-ascending dose study: safety, biomarker, pharmacokinetics and exposure-response relationships of ALXN1210, a humanized monoclonal antibody to C5, with marked half-life extension and potential for significantly longer dosing intervals. Blood. 2015;126(23):4777.","journal-title":"Blood"},{"key":"1877_CR16","doi-asserted-by":"crossref","unstructured":"Vu T, Ortiz S, Katsuno M, et al. Pharmacokinetics and pharmacodynamics of ravulizumab in adults with generalized myasthenia gravis: results from the phase 3 CHAMPION MG study (abstract no. P3-1.002) Neurology. 2022;98(Suppl. 18):850.","DOI":"10.1212\/WNL.98.18_supplement.850"},{"issue":"1","key":"1877_CR17","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/cen3.12738","volume":"14","author":"T Vu","year":"2023","unstructured":"Vu T, Meisel A, Mantegazza R, et al. Long-term efficacy and safety of ravulizumab in generalized myasthenia gravis: phase 3 CHAMPION MG study open-label extension [abstract]. Clin Exp Neuroimmunol. 2023;14(1):69\u201373.","journal-title":"Clin Exp Neuroimmunol."},{"issue":"1","key":"1877_CR18","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/cen3.12738","volume":"14","author":"A Uzawa","year":"2023","unstructured":"Uzawa A, Juel V, Vu T, et al. Efficacy of ravulizumab across sex and age subgroups of patients with generalized myasthenia gravis: a post hoc analysis of the CHAMPION MG study [abstract]. Clin Exp Neuroimmunol. 2023;14(1):69\u201373.","journal-title":"Clin Exp Neuroimmunol."},{"issue":"1","key":"1877_CR19","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/cen3.12731","volume":"14","author":"S Suzuki","year":"2023","unstructured":"Suzuki S, Howard JF Jr, Vu T, et al. Ravulizumab efficacy in generalized myasthenia gravis by the time from diagnosis [abstract]. Clin Exp Neuroimmunol. 2023;14(1):69\u201373.","journal-title":"Clin Exp Neuroimmunol."},{"issue":"Suppl. 1","key":"1877_CR20","first-page":"S2","volume":"65","author":"T Vu","year":"2022","unstructured":"Vu T, Meisel A, Mantegazza R, et al. Long-term efficacy and safety of ravulizumab, a long-acting terminal complement inhibitor, in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG open-label extension. Muscle Nerve. 2022;65(Suppl. 1):S2\u20133.","journal-title":"Muscle Nerve"},{"issue":"6","key":"1877_CR21","doi-asserted-by":"publisher","first-page":"3050","DOI":"10.1007\/s00415-021-10891-1","volume":"269","author":"S Lehnerer","year":"2021","unstructured":"Lehnerer S, Jacobi J, Schilling R, et al. Burden of disease in myasthenia gravis: taking the patient\u2019s perspective. J Neurol. 2021;269(6):3050\u201363.","journal-title":"J Neurol"},{"issue":"1","key":"1877_CR22","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s13760-019-01209-0","volume":"120","author":"BK Vitturi","year":"2019","unstructured":"Vitturi BK, Pellegrinelli A, Valerio BCO. Medication adherence in patients with myasthenia gravis in Brazil: a cross-sectional study. Acta Neurol Belg. 2019;120(1):83\u20139.","journal-title":"Acta Neurol Belg"},{"key":"1877_CR23","unstructured":"Parthan A, Johnston K, Govindarajan R. Economic impact of treating generalized myasthenia gravis with ravulizumab vs eculizumab: US payer perspective [abstract no. G45]. J Manag Care Spec Pharm. 2022;28(Suppl. 3-a):S53\u20134."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-023-01877-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-023-01877-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-023-01877-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T18:51:24Z","timestamp":1702407084000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-023-01877-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,11]]},"references-count":23,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["1877"],"URL":"https:\/\/doi.org\/10.1007\/s40265-023-01877-6","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,11]]},"assertion":[{"value":"14 April 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Connie Kang is a salaried employee of Adis International Ltd\/Springer Nature and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}